Analysts Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $11.25

Novavax, Inc. (NASDAQ:NVAX) has been assigned a consensus recommendation of “Hold” from the nine research firms that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $11.25.

Several brokerages have commented on NVAX. JPMorgan Chase & Co. dropped their price target on Novavax from $7.00 to $6.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novavax in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, January 20th. B. Riley Financial restated a “buy” rating and set a $16.00 price target (down from $18.00) on shares of Novavax in a research note on Monday, November 10th. Finally, TD Cowen reduced their price objective on Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Tuesday, November 4th.

Institutional Investors Weigh In On Novavax

Institutional investors and hedge funds have recently bought and sold shares of the business. Flagship Harbor Advisors LLC bought a new position in shares of Novavax during the 4th quarter worth about $33,000. Quarry LP bought a new position in Novavax during the third quarter worth about $33,000. State of Wyoming acquired a new stake in Novavax during the second quarter valued at approximately $52,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Novavax by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,617 shares during the period. Finally, Danske Bank A S acquired a new position in shares of Novavax in the 3rd quarter worth approximately $64,000. Institutional investors own 53.04% of the company’s stock.

Novavax Price Performance

NASDAQ NVAX opened at $11.19 on Friday. Novavax has a 1 year low of $5.01 and a 1 year high of $11.97. The company has a fifty day simple moving average of $8.27 and a 200 day simple moving average of $8.02. The company has a current ratio of 2.27, a quick ratio of 2.24 and a debt-to-equity ratio of 5.93. The company has a market cap of $1.82 billion, a P/E ratio of 6.25 and a beta of 2.58.

Novavax (NASDAQ:NVAX) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.77. The firm had revenue of $136.40 million during the quarter, compared to analyst estimates of $90.26 million. Novavax had a net margin of 32.10% and a negative return on equity of 217.02%. The business’s revenue was up 66.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.51) EPS. On average, sell-side analysts predict that Novavax will post -1.46 EPS for the current year.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Q4 beat — Novavax reported a surprise GAAP profit (EPS $0.11) and materially beat revenue expectations (Q4 revenue ~ $147M), driving the initial rally. Article Title
• Positive Sentiment: Raised 2026 adjusted revenue outlook — management said milestone and licensing payments (from partners) should offset weaker end-market demand, supporting revenue expectations for 2026. Article Title
• Positive Sentiment: Partnerships and milestones — Company highlighted a $225M Sanofi milestone earned in 2025 and a January 2026 non‑exclusive Matrix‑M licensing agreement with Pfizer, which underpin near-term cash generation and validation of the adjuvant platform. Article Title
• Positive Sentiment: Solid balance sheet and cost progress — Novavax ended 2025 with roughly $751M in cash and reported R&D and SG&A reductions, reducing financing risk and increasing runway for pipeline work. Article Title
• Neutral Sentiment: Investor events — Management will present at upcoming investor conferences (TD Cowen fireside chat on March 3), which gives investors a chance to hear management’s outlook and Q&A. Article Title
• Neutral Sentiment: Earnings call transcript available — The full Q4 earnings call transcript and slides give detail on product deliveries, milestone timing and pipeline timing for investors who want to dig deeper. Article Title
• Negative Sentiment: Cautious FY‑2026 revenue guide — Management issued FY‑2026 revenue guidance (approximately $230M–$270M), which is well below consensus estimates and implies near‑term demand weakness; this tempered some upside despite the beat. (Guidance disclosed in company materials and filings.)

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.